Forxiga becomes the first new treatment option for CKD patients in nearly 20 years
News
Researchers find HPV vaccine cuts cervical cancer by 87%
The research paper, published in the Lancet and funded by Cancer Research UK, considered all cervical cancers diagnosed in England among women aged 20-64 between January 2006 and June 2019
UK approval for MSD/Ridgeback’s COVID-19 antiviral med
The antiviral medicine will be marketed with the trademark name Lagevrio in the UK
Guardant Health and Royal Marsden NHS Foundation Trust announce partnership
Partnership will establish an in-house liquid biopsy testing service, using Guardant Health’s proprietary digital sequencing platform
NICE recommends Namuscla for NHS to treat genetic disorder
It is estimated that around 250 people will be eligible to have Namuscla
Novartis signs $1.3bn deal with UK-based Dunad
Dunad will apply its own platform to generate the novel covalent and targeted protein degrading small molecule drugs
ICEBERG study demonstrates improved outcomes of nasal spray for TRD
Back in 2019, esketamine was commercialised as Spravato, described as a “breakthrough” medication used to treat depression
EMA ends rolling review for COVID antibodies
Bamlanivimab and etesevimab are intended for use in COVID patients at high risk of disease progression
First authorisation for Novavax COVID-19 jab announced
Indonesia becomes the first country to authorise the vaccine
Global vaccine trade surpasses $42 billion
Belgium leads in country rankings by the value of exports this year, followed by Germany and the US
Study reveals lack of diagnostic accuracy in online consultations
93% of clinicians felt that remote medicine was worse than in-person consultations in terms of accuracy
AZ to transfer certain drug rights to Covis Pharma for $270m
AstraZeneca has announced it will transfer global rights to respiratory meds Eklira and Duaklir to Covis Pharma
UK government to cut cost of repeatable HRT prescriptions
HRT treats menopause symptoms by replacing hormones that are at a lower level for those experiencing it
Walk-in centres for COVID booster jabs open across England
Anyone who received their second dose at least six months ago can now receive their booster at one of these sites
Gilead and MSD collab on Trodelvy/Keytruda breast cancer trial
The companies will evaluate Trodelvy plus Keytruda for the first-line treatment of certain triple-negative breast cancer patients
